Royal Bank of Canada Reaffirms Outperform Rating for Acadia Healthcare (NASDAQ:ACHC)

Acadia Healthcare (NASDAQ:ACHC)‘s stock had its “outperform” rating restated by investment analysts at Royal Bank of Canada in a note issued to investors on Friday, Benzinga reports. They currently have a $94.00 price target on the stock. Royal Bank of Canada’s target price suggests a potential upside of 21.65% from the stock’s current price.

Several other brokerages have also recently weighed in on ACHC. Cantor Fitzgerald reiterated a “neutral” rating and set a $90.00 price target on shares of Acadia Healthcare in a research report on Monday, August 19th. Deutsche Bank Aktiengesellschaft boosted their target price on shares of Acadia Healthcare from $70.00 to $75.00 and gave the company a “hold” rating in a research note on Friday, August 2nd. Finally, Barclays dropped their price target on shares of Acadia Healthcare from $89.00 to $83.00 and set an “overweight” rating on the stock in a research report on Thursday, August 1st. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Acadia Healthcare currently has a consensus rating of “Moderate Buy” and a consensus price target of $87.44.

Acadia Healthcare Stock Performance

ACHC traded down $0.17 during trading on Friday, reaching $77.27. 42,912 shares of the company’s stock were exchanged, compared to its average volume of 783,354. The company’s fifty day simple moving average is $73.34 and its 200-day simple moving average is $72.12. The stock has a market capitalization of $7.17 billion, a P/E ratio of -551.43, a price-to-earnings-growth ratio of 2.22 and a beta of 1.30. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.18 and a quick ratio of 1.18. Acadia Healthcare has a 1 year low of $62.04 and a 1 year high of $87.77.

Acadia Healthcare (NASDAQ:ACHC) last posted its quarterly earnings results on Wednesday, July 31st. The company reported $0.91 EPS for the quarter, beating the consensus estimate of $0.87 by $0.04. The company had revenue of $796.00 million for the quarter, compared to analyst estimates of $784.38 million. Acadia Healthcare had a negative net margin of 0.17% and a positive return on equity of 11.42%. The firm’s revenue was up 8.8% on a year-over-year basis. During the same period in the prior year, the company earned $0.92 earnings per share. As a group, research analysts predict that Acadia Healthcare will post 3.51 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of ACHC. Blue Trust Inc. lifted its holdings in Acadia Healthcare by 86.1% in the 2nd quarter. Blue Trust Inc. now owns 536 shares of the company’s stock valued at $36,000 after purchasing an additional 248 shares in the last quarter. Mather Group LLC. purchased a new position in shares of Acadia Healthcare in the first quarter worth about $48,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in Acadia Healthcare during the second quarter worth about $59,000. nVerses Capital LLC purchased a new stake in Acadia Healthcare during the 2nd quarter valued at about $95,000. Finally, Innealta Capital LLC acquired a new stake in Acadia Healthcare in the 2nd quarter valued at about $164,000.

About Acadia Healthcare

Acadia Healthcare Company, Inc provides behavioral healthcare services in the United States and Puerto Rico. The company develops and operates acute inpatient psychiatric facilities, specialty treatment facilities comprising residential recovery facilities and eating disorder facilities, comprehensive treatment centers, and residential treatment centers, as well as facilities offering outpatient behavioral healthcare services for the behavioral healthcare and recovery needs of communities.